Publication | Closed Access

Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission

Lymphoid NeoplasiaRadiation OncologyHodgkin LymphomaTransplantationMarrow TransplantationCell TherapyMedicineStem Cell TransplantationImmunologyHematologyEarly RelapseImmunotherapyOncologyCell TransplantationBrentuximab VedotinHealth Sciences